August 2017

Important New Products

• Alecensa (alectinib) is a tyrosine kinase inhibitor that targets anaplastic lymphoma  kinase ...(more)
• Obizur (susoctocog alfa (bhk)) is a recombinant analogue of porcine coagulation factor VIII, ...(more)
• Pedea (ibuprofen)  is indicated for the treatment of haemodynamically significant patent ...(more)

New Indications

• Atozet (ezetimibe/atorvastatin (as calcium trihydrate))  is now also indicated in patients with ...(more)
• Opdivo (nivolumab (rch))  as monotherapy is now also indicated for the treatment of ...(more)

New Contraindications

• DBL Dexamethasone Sodium Phosphate Injection (dexamethasone phosphate (as ...(more)
• Kaletra (lopinavir/ritonavir)  should not be coadministered with elbasvir/grazoprevir. ...(more)
• Coadministration of Videx (didanosine) with stavudine is now contraindicated due to the ...(more)

Active Ingredient Naming Changes

In this release, MIMS Australia will be including the following INNs (International Non-proprietary Names) as well as Australian Approved Names (AANs) as part of our push to support the Therapeutic Goods Administration (TGA) active ingredient name changes project.  

MIMS will begin referring to these ingredients by their new names, however, users may continue to search by the old AANs if preferred. ...(more)